Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olatorepatide in Overweight or Obesity Without Diabetes
NCT07896265Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2026
- Primary completion
- Dec 2028
01
Overview
A Phase 3 trial of olatorepatide in obesity, sponsored by Regeneron Pharmaceuticals. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
olatorepatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07896265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07896265.